For a UK CFO, the question is rarely “can we get a grant?” but “how do Innovate UK grants improve our overall cost of capital, runway and risk profile?” Grants are one instrument in a wider funding stack that also includes equity, debt and R&D tax relief. Used intelligently, they can sharpen returns without overloading the balance sheet.

Innovate UK grants as one pillar of the capital stack

Innovate UK grants support R&D and commercialisation projects that are too risky for traditional lenders and often too early for mainstream institutional capital. They typically:

• Cover a proportion of eligible project costs
• Focus on clearly defined innovation outcomes
• Require match funding and evidence of commercial potential

At the same time, Innovate UK has broadened its toolkit to include innovation loans, designed as flexible, patient capital for late stage R&D projects. For a finance leader, this means public innovation funding is no longer a single grant decision but a portfolio of non dilutive and quasi debt options that can be blended with private capital.

Equity: strategic but dilutive

Equity remains the default choice for many high growth businesses, especially in sectors like AI, fintech and life sciences. The British Business Bank’s Small Business Equity Tracker shows that the UK is now the third largest venture capital market in the world, even though deal volumes and values have cooled since 2021. 

From a CFO’s perspective, equity has several characteristics:

• High implicit cost of capital once future exits are priced in
• Permanent dilution of founders and early shareholders
• Strong investor influence over strategy, milestones and reporting

Equity is often essential for large, high risk programmes, but issuing too much too early locks in a high cost of capital and can make later fundraising rounds more complex.

Used in combination, Innovate UK grants can reduce the amount of equity required to reach key value inflection points, such as first in human trials, regulatory approval or commercial pilot deployment. That allows CFOs to negotiate from a position of greater traction and potentially higher valuation.

Debt: disciplined but constrained

Conventional debt and venture debt provide non dilutive capital, but they introduce fixed repayment schedules, covenants and refinancing risk. In the current interest rate environment, many smaller businesses remain reluctant to borrow, with surveys indicating a preference for slower growth over taking on new debt. The Times

Compared with commercial debt, Innovate UK innovation loans and grants can:

• Offer more flexible repayment structures and longer tenors than standard bank finance UKRI
• Tolerate higher technical risk where there is a strong innovation case
• Improve lenders’ confidence by validating the technology and business model

For CFOs, the practical issue is sequencing. A well structured plan might use grants and innovation loans to fund technical de risking, followed by debt facilities for working capital once revenues become more predictable.

R&D tax relief: retrospective, scalable cash support

While grants and equity are forward looking, R&D tax relief operates retrospectively. Claims are calculated on qualifying expenditure already incurred and realised through cash payments or reduced corporation tax.

In a funding strategy, R&D tax relief can:

• Recycle a portion of R&D spend back into future innovation cycles
• Provide a predictable cash benefit once methodology and record keeping are mature
• Strengthen Innovate UK applications by demonstrating a consistent commitment to innovation investment

Crucially, CFOs must manage the interaction rules. Grants and some forms of notified state aid can reduce the proportion of costs that qualify for SME R&D relief. The modelling challenge is to optimise the blend of grant, loan and tax relief rather than treating each instrument in isolation.

How Innovate UK grants reshape cost of capital

A simplified way for a CFO to view the stack is:

• Equity: high cost of capital, high risk tolerance, no repayments
• Debt: medium cost of capital, fixed repayments, security or covenants
• Innovate UK grants: zero direct cost of capital, strict eligibility and reporting, non dilutive
• Innovation loans: lower cost than equity, more flexible than commercial debt, linked to innovation risk
• R&D tax relief: indirect reduction in cost of capital through cash refunds or tax savings

Properly integrated, Innovate UK grants can lower the blended cost of capital for a portfolio of projects, enabling investments that would otherwise fail hurdle rates. For example, a manufacturing business might fund a £3 million decarbonisation project through a mix of 50 per cent grant, 25 per cent equity and 25 per cent debt, with R&D tax relief recycling part of the residual cost. The resulting internal rate of return can look very different from a 100 per cent equity or debt funded scenario.

Specialist funding advisers play a growing role in helping CFOs design and execute these blended strategies. Consultancy FI Group, which focuses on innovation funding, R&D tax relief and grant support, often works with finance leaders to:

• Map innovation roadmaps to relevant Innovate UK grant and loan opportunities
• Model the interaction between grants, innovation loans, debt and R&D tax credits across multiple financial years
• Improve the robustness of project costings, eligibility assumptions and evidence required for both grant audits and tax enquiries

Because FI Group operates across grants and tax, its advisers can highlight where an attractive grant might sharply reduce R&D tax relief, or where a smaller grant combined with a stronger tax position delivers a better long term outcome. For CFOs, this integrated view of non dilutive funding is often more valuable than narrow advice on a single scheme. 

Practical steps for CFOs

To make Innovate UK grants work effectively alongside equity, debt and R&D tax relief, finance leaders can:

1. Build a three to five year innovation funding roadmap that aligns key technical milestones with the likely timing of Innovate UK calls, innovation loans and tax claims.
2. Quantify the blended cost of capital for different funding mixes, including sensitivity to grant success or failure.
3. Stress test cash flow around grant payment schedules and potential delays in R&D tax repayments.
4. Engage early with potential equity and debt providers so that public funding decisions feed into, rather than delay, future rounds.
5. Use specialist funding advisers’ guidance, such as that provided by FI Group, to validate eligibility assumptions, avoid double counting and prepare for scrutiny from both Innovate UK and HMRC.

For a modern UK CFO, Innovate UK support is not a side project delegated to technical teams. It is a lever within the capital structure that can reduce risk, protect shareholder value and unlock innovation that would otherwise remain on the shelf.